Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211219 | 1.00 | MAPT (0.73) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL8211228 | 1.00 | MAPT (0.73) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL8211222 | 1.00 | MAPT (0.73) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL14213566 | 0.85 | MEN1 (0.71) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL8205013 | 0.85 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL8205017 | 0.85 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL8205015 | 0.85 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL10492259 | 0.84 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1315178 | 0.84 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL24129903 | 0.83 | CISD1 (0.67) | MAPTMEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885MEN1 2329/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.